Bayer's Pharma Engine Delivers, but the Cash Register Still Runs Negative

Bayer's third-quarter report card lands with a split verdict: the medicine cabinet is performing, the bank account is not. Shares rose 4.0% on the day as investors focused on a pharma division that grew faster than expected, yet the same set of numbers showed free cash flow stuck at minus €293 million for the quarter — a reminder that operating progress and financial relief remain two separate stories at this company.

The headline figures explain the market's mood. Group revenue for Q3 2026 came in at €10.053 billion, up 4.1% year on year, while EBITDA before special items advanced 6.9% to €1.615 billion — outpacing the top line. The pharmaceuticals unit did the heavy lifting, with sales climbing 8% to €4.68 billion and EBITDA before special items jumping 23.6% to €1.292 billion. Two products stood out: Nubeqa and Kerendia posted currency- and portfolio-adjusted growth of 58.3% and 64.9% respectively.

Guidance Raised, but the Cash Gap Persists

Management responded to the momentum by lifting its full-year 2026 targets. Group EBITDA before special items is now guided at €9.8 billion to €10.3 billion, and the pharma division's EBITDA margin is expected to reach 25% to 27%. The free-cash-flow forecast was improved by €1.0 billion — yet it still points to an outflow of €1.5 billion to €0.5 billion. Net financial debt at year-end is projected at €28.0 billion to €29.0 billion.

That distinction matters more than the direction of the revision. A result at the better end of the cash range would support the case that operational gains are translating into real financial headroom; a figure at the weaker end would show how much of the improvement is still being swallowed by obligations elsewhere. Even the optimistic scenario does not deliver positive free cash flow — only a smaller drain.

Should investors sell immediately? Or is it worth buying Bayer?

The quarterly net loss of €672 million sharpens the picture. According to Dow Jones, impairment charges on Xofigo and Claritin totaling €522 million, together with legal costs, weighed on the bottom line. The loss on its own therefore captures neither the operating momentum nor the liquidity position in full.

Where the Cracks Are

The bear case does not require a pharma slowdown. Continued weakness elsewhere plus heavy legal payouts could be enough to cap the financial relief. Crop Science EBITDA before special items fell 41.3% to €101 million in the quarter — a reminder that the recovery is not evenly spread across the portfolio.

Then there is litigation. Bayer expects roughly €5 billion in related cash outflows for 2026, a scale that explains why better adjusted earnings do not automatically produce positive free cash flow. Full legal clarity would be premature even with progress on the glyphosate front: Business Insider reports PCB claims tied to the Monsanto acquisition, and CEO Bill Anderson reportedly expects further proceedings in the coming quarters. The risk is not confined to a single pending ruling.

The Courtroom Calendar Is the Next Catalyst

The most immediate catalyst is the pending court decision on the Roundup settlement. Reuters reports that Anderson expects approval before Christmas, possibly within the coming weeks. The $7.25 billion settlement covers US cancer claims and is under review by a court in Missouri. Approval would raise planning certainty but would be neither a completed agreement nor the end of all legal exposure; a delay would leave the uncertainty in place.

Bayer at a turning point? This analysis reveals what investors need to know now.

Analyst sentiment leans constructive. JPMorgan reaffirmed its "Overweight" rating on Bayer following the results, keeping a price target of €61. BofA Global Research argues the pharma division's potential is massively underestimated and points to multi-year cash-flow opportunities — the core of the bull case, which rests not on one strong quarter but on a durable improvement in cash generation.

For that thesis to hold, drug growth must feed through into persistently higher earnings, and the guided 25%–27% pharma margin provides the operating yardstick. Whether it produces correspondingly more free cash remains a separate question — and the one shareholders will keep asking until the outflow turns positive.

Ad

Bayer Stock: New Analysis - 3 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...